(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Main 15 Applications for Efficiency and Association - 2'A prank': Israel Police detain suspect for shooting rubber bullets at Ashkelon kindergarten
- 3Coalition led by Iraqi PM al-Sudani wins parliamentary elections
- 4Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- 5The Specialty of Compromise: Examples from Reality
- Careful Nurturing: Techniques for Bringing up Tough Children
- Step by step instructions to Explore the Close to home Consequence of Cellular breakdown in the lungs
- Scientists document a death from a meat allergy tied to certain ticks
- Bitcoin momentum builds in Abu Dhabi as global interest surges
- One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
- Europe’s Airlines Run Low on Fuel
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- The powerful new Rubin Observatory just found 11,000 new asteroids and measured 'tens of thousands more'
- At least 30 killed in attack on Nigeria village
